TABLE S1. Phenotypic resistance characteristics of the isolates

Isolate	Inhibition zone diameter (mm)[a, b]				Minimum inhibitory concentration (mg/L)[a, c]								
	IPM	**AMK**	**GEN**	**SXT**	**IPM**	**MEM**	**AMK**	**GEN**	**TOB**	**CIP**	**SXT**	**CST**	**TGC**
K51-65	8	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	0,5	4
K51-66	9	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	1	4
K51-67	10	21	9	6	>32	≥32	4	32	2	1	2	1	2
K51-68	6	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	1	4
K51-69	6	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-70	6	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	0,5	4
K51-71	6	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-72	13	6	6	6	>32	32	>256	>1024	>1024	>32	>32	1	4
K51-73	13	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-74	12	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-75	6	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-76	6	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-77	10	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	0,5	4
K51-78	9	6	6	6	>32	32	>256	>1024	>1024	>32	>32	0,5	8
K51-79	11	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	0,5	4
K51-80	10	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K51-81	9	6	6	6	32	32	>256	>1024	>1024	>32	>32	0,5	4
K70-64	9	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	0,5	4
K70-65	9	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-66	12	29	17	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-67	11	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-68	10	28	16	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-69	13	28	24	6	≥32	16	1	2	0,25	>32	>32	0,5	4
K70-70	10	6	6	6	>32	>32	>256	>1024	>1024	>32	>32	0,5	4
K70-71	13	30	17	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-72	13	29	15	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-73	12	29	18	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-74	13	29	17	6	>32	>32	1	12	0,5	>32	>32	0,5	8
K70-75	15	30	18	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-76	14	30	15	6	16	16	1	12	0,5	>32	>32	0,5	4
K70-77	7	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-78	6	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-79	6	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-80	10	6	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND
K70-81	8	25	6	6	ND	ND	ND	ND	ND	ND	ND	ND	ND

[a] IPM, imipenem; AMK, amikacin; GEN, gentamicin; SXT, trimethoprim/sulfamethoxazole; MEM, meropenem; TOB, tobramycin; CIP, ciprofloxacin; CST, colistin; TGC, tigecycline; ND, not determined.

[b] Determined by agar disc diffusion.

[c] Determined by Etest.

TABLE S2. Primers used for molecular detection and characterization of the class 1 integron and AbaR resistance islands.

Primer[a]	**Sequence 5'-3'**	**Target site**	**Reference**
5'CS (F)	GCCTGTTCGGTTCGTAAGCT	5'CS	Toleman *et al*., 2007
aac(6`)-Ib-F (F)	TTGCGATGCTCTATGAGTGGCTA	*aacA4*	Karah *et al*., 2011
aac(6`)-Ib-R (R)	CTCGAATGCCTGGCGTGTTT	*aacA4*	Karah *et al*., 2011
catB8-R (R)	GCACCGTCTCCAATTTTGAT	*catB8*	Karah *et al*., 2011
catB8-F2 (F)	AGATGGAGTGGTGGAACTGG	*catB8*	Karah *et al*., 2011
aadA1-F (F)	CGCCGAAGTATCGACTCAAC	*aadA1*	Karah *et al*., 2011
aadA1-FR (R)	GATGACGCCAACTACCTCTG	*aadA1*	Karah *et al*., 2011
aadA1-F2 (F)	TATCCAGCTAAGCGCGAACT	*aadA1*	Karah *et al*., 2011
aadA1-R (R)	GACTACCTTGGTGATCTCGC	*aadA1*	Karah *et al*., 2011
3'CS (R)	CGGATGTTGCGATTACTTCG	3'CS	Toleman *et al*., 2007
comM-1 (F)	CAACCCTGTCTTTGCATTTG	*comM*	This study
Tn6022a-1 (R)	GGGTCGATTCAAACCAAATG	*tniC*	This study
Tn6022a-2 (F)	CCATCGTTTTGCTGCTGATA	*tniC*	This study
Tn6022a-3 (R)	AGCAATCTGCCAAGCTTCAT	*tniA*	This study
Tn6022a-4 (F)	CGAGGTTGGACAACTGAAAAA	*tniA*	This study
Tn6022a-5 (F)	GCAGCGTGGGACTTATGATT	*tniA*	This study
Tn6022a-6 (R)	CCATTTAACGATTGGGGATG	*tniA*	This study
Tn6022a-7 (F)	CTCCAGCAAAAGCCAATGTT	*tniB*	This study
Tn6022a-8 (R)	TGCCTCACGAGTACCAACAC	*tniB*	This study
Tn6022a-9 (F)	AGATGCCGAAAGATTCGATG	*tniD*	This study
Tn6022a-10 (R)	GCCACATGTCGTACAGATCG	*tniD*	This study
Tn6022a-11 (F)	CATGGATGCAACCAGTCTGT	*tniE*	This study
Tn6022a-12 (R)	TCGCATAAATCAGCACAACC	*tniE*	This study
Tn6022a-13 (F)	AATACGTTCAGCGAGGTTGG	*tniE*	This study
Tn6022a-14 (R)	TTGCCCATTAAGCACAACAG	*tniE*	This study
Tn6022a-15 (F)	TCTTTTTGTTCTTGAGCTTGCTT	*orf3*	This study
Tn6022a-16 (R)	AGGCGATTGCCTTAATGTGA	*orf3*/*uspA*	This study
Tn6022a-17 (F)	CCCAAGAGAGCTGATTTTGC	*uspA*	This study
Tn6022a-18 (R)	CAAAAGCAAAAGCACCACAA	*uspA*	This study
Tn6022a-19 (F)	TCGACTTCTGTTCCTTCACG	*sup*	This study
Tn6022a-20 (F)	CCTTGCCCTTTACATTCTCG	*sup*	This study
Tn6022a-21 (R)	CGGATACGCTTCCAATTTTC	*sup*	This study
Tn6022a-22 (F)	GGATCAACGCCTGCAATAAT	*sup*	This study
Tn6022a-23 (R)	GAAAATGCCAAGGGAATAAAAA	*orf4*	This study
Tn6022a-24 (F)	AAAAGCTTTGTGGGATGTGG	*orf4*	This study
Tn6022a-25 (R)	AAAATCAGAAAGCCATATGAAGAT	*orf4*	This study
Z1-1 (F)	AAGGTGCTTACCGAATGCAA	*orf1-Z1*	This study
Z1-2 (R)	ACGAGAAAGCGAAGAAGTGG	*orf1-Z1*	This study
Z1-3 (F)	CGTGGCATACCATCATCAAG	*orf2-Z1*	This study
Z1-4 (R)	GCGGATGAAGTGATGGAGTT	*orf3-Z1*	This study
Z1-5 (F)	TTATTTAACGCCGGAGCATC	*orf3-Z1*	This study
Z1-6 (R)	GCTGCGGTAGCTGGTAATTC	*orf3-Z1*	This study
Z1-7 (F)	TTCAGCCCATTTCTGAGCTT	*orf3-Z1*	This study
Z1-8 (R)	CTGGTGGTAATGGAGCTGGT	*orf3-Z1*	This study
Z1-9 (F)	TTTGAACGACCATCAAGCAC	*int-Z1*	This study
Z1-10 (R)	TACTATGGCCCAGCATTTCC	*int-Z1*	This study
Z1-11 (F)	TTGTTCAAGCTAACGGCGTA	*orf6-Z1*	This study
Z1-12 (R)	GGCCAAAAGGATGTGGAGTA	*orf6-Z1*/*orf7-Z1*	This study
Tn6022b (R)	ACCTGTTCCTGCTGTCGTCT	*tniAb*	This study
Z2-1 (F)	GCGAAATCATCTGCCAAACT	*sul2*	This study
Z2-2 (R)	CTTTGCCACGAATACCGTCT	*glmM*	This study
Z2-3 (F)	TGCCCTCTTGGGTTATCAAG	*rcr2*/*tetA*	This study
ISAba1-out (R)	GCGCTTGACAGACCCTAGAC	IS*Aba1*	This study

ISAba1B (F)	CATGTAAACCAATGCTCACC	IS*Aba1*	Poirel & Nordmann, 2006
ISAba1A (R)	GTGCTTTGCGCTCATCATGC	IS*Aba1*	Poirel & Nordmann, 2006
Tn2006-1 (F)	TTGGCTCAACTTTATGATCCTG	*yeeA*	This study
Tn2006-2 (R)	ATGGGCTTCGTCATTCATTG	ATPase	This study
OXA-23-like-R (F)	ATTTCTGACCGCATTTCCAT	$bla_{\text{OXA-23-like}}$	Woodford *et al*., 2006
OXA-23-like-F (R)	GATCGGATTGGAGAACCAGA	$bla_{\text{OXA-23-like}}$	Woodford *et al*., 2006
Z2-4 (F)	TAATCCAAATCCAGCCATCC	*tetA*	This study
Z2-5 (R)	TTTTCATTAGCGGGTCTTGG	*tetA*	This study
Z2-6 (F)	CTCCTGTGATCCCTGAAAGC	*tetA*	This study
Z2-7 (R)	GGCGAGTTTACGGGTTGTTA	*tetR*	This study
Z2-8 (F)	TGCAGAGCCAGCCTTCTTAT	*tetR*	This study
Z2-9 (R)	ATCAAAATGCTGCGTTCACA	*tetR*/*rcr2*	This study
Z2-10 (F)	CTGTTTTCGACATCCCGTTC	*rcr2*	This study
Z2-11 (R)	CACTWCCACATGCTGTKKC	*rcr2*	This study
Z2-12 (R)	CCCTGGGAACACATCAATCT	*rcr2*/*strB*	This study
Z2-13 (F)	CATTGCTCATCATTTGATCGGCT	*strB*	This study
Z2-14 (R)	TATCTGCGATTGGACCCTCTG	*strA*	This study
Z2-15 (F)	AATTGCCGTTATCACCAAGC	*strA*	This study
orf4b (R)	TGGACGCTACGTTGTGAAAG	*orf4b*	This study
comM-2 (R)	GCCAGCAAGCTCAGCATAA	*comM*	This study

[a] F, forward; R, reverse; Z1, zone 1; Z2, zone 2.

References for Table S2

Karah N, Haldorsen B, Hermansen NO, Tveten Y, Ragnhildstveit E, Skutlaberg DH, Tofteland S, Sundsfjord A, Samuelsen O. 2011. Emergence of OXA-carbapenemase- and 16S rRNA methylase-producing international clones of *Acinetobacter baumannii* in Norway. J. Med. Microbiol. **60**:515-521.

Poirel L, Nordmann P. 2006. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene $bla_{\text{OXA-58}}$ in *Acinetobacter baumannii*. Antimicrob. Agents Chemother. **50**:1442-1448.

Toleman MA, Vinodh H, Sekar U, Kamat V, Walsh TR. 2007. $bla_{\text{VIM-2}}$ harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence. Antimicrob. Agents Chemother. **51**:2636-2638.

Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SGB, Livermore D.M. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. Int. J. Antimicrob. Agents. **27**:351-353.

TABLE S3. PCR assays used for sequencing and detection of *aacA4-catB8-aadA1* and AbaR25.

PCR[a]	Primers forward/reverse	Amplicon size (base pair)	Application
S1	5'CS/3'CS	2636	Sequencing of *aacA4-catB8-aadA1* in K51-65
L1	comM-1/Z1-4	11731	Sequencing of AbaR25 in K51-65
L2	Z1-3/Z2-2	10262	
L3	Z2-1/Tn2006-2	13148	
L4	Tn2006-1/comM-2	14597	
L5	comM-1/Tn2006-2	12761	Sequencing of AbaR4 in K51-67
L4	Tn2006-1/comM-2	6115	
L1	comM-1/Z1-4	11731	Sequencing of ΔAbaR25 in K51-74
L6	Z1-3/Tn2006-2	17267	
L4	Tn2006-1/comM-2	14597	
S1	5'CS/3'CS	2636	Detection of *aacA4-catB8-aadA1*
S2	5'CS/aadA1-FR	1683	
S3	5'CS/catB8-R	1337	
S4	5'CS/aac(6')-Ib-R	820	
S5	comM-1/comM-2	850	Detection of AbaR25
S6	comM-1/Tn6022a-6	2589	
S7	comM-1/Tn6022a-16	4717	
S8	Tn6022a-15/Tn6022a-25	4281	
S9	Tn6022a-24/Z1-2	1694	
S10	Z1-5/Tn6022a-1	4087	
S11	Z1-11/ISAba1-out	4280	
S12	Tn6022a-5/Z2-2	3306	
S13	Z2-1/Tn6022a-6	3246	
S14	Tn6022a-9/Tn6022a-14	2342	
S15	Tn6022a-22/OXA-23-like-F	3420	
S16	OXA-23-like-R/Tn6022a-25	3445	
S17	Tn6022a-24/Z2-9	3460	
S18	Z2-8/Z2-14	3618	
S19	Z2-13/comM-2	4015	
S20	Tn6022a-24/comM-2	1415	

[a] S, standard; L, long.

TABLE S4. Results of PCR-based detection of *aacA4-catB8-aadA1* and AbaR25 among the isolates[a]

Isolate	S1	S2, S3, S4	S5	S6	S7, S8, S9	S10, S11, S12, S13	S14, S15, S16	S17, S18, S19	S20
K51-65	+	+	-	+	+	+	+	+	+
K51-66	+	+	-	+	+	+	+	+	+
K51-67	-	ND	-	+	-	-	+	-	+
K51-68	-	ND	-	+	+	+	+	+	+
K51-69	+	+	-	+	+	+	+	+	+
K51-70	+	+	-	+	+	+	+	+	+
K51-71	+	+	-	+	+	+	+	+	+
K51-72	+	+	-	+	+	+	+	+	+
K51-73	+	+	-	+	+	+	+	+	+
K51-74	+	+	-	+	+	-	+	+	+
K51-75	+	+	-	+	+	+	+	+	+
K51-76	+	+	-	+	+	+	+	+	+
K51-77	-	ND	-	+	+	+	+	+	+
K51-78	+	+	-	+	+	+	+	+	+
K51-79	+	+	-	+	+	+	+	+	+
K51-80	+	+	-	+	+	+	+	+	+
K51-81	-	ND	-	+	+	+	+	+	+
K70-64	+	+	-	+	+	+	+	+	+
K70-65	+	+	-	+	+	+	+	+	+
K70-66	-	ND	-	+	+	+	+	+	+
K70-67	+	+	-	+	+	+	+	+	+
K70-68	-	ND	-	+	+	+	+	+	+
K70-69	-	ND	-	+	+	+	+	+	+
K70-70	+	+	-	+	+	+	+	+	+
K70-71	-	ND	-	+	+	+	+	+	+
K70-72	-	ND	-	+	+	+	+	+	+
K70-73	-	ND	-	+	+	+	+	+	+
K70-74	-	ND	-	+	+	+	+	+	+
K70-75	-	ND	-	+	+	+	+	+	+
K70-76	-	ND	-	+	+	+	+	+	+
K70-77	+	+	-	+	+	+	+	+	+
K70-78	-	ND	-	+	+	+	+	+	+
K70-79	+	+	-	+	+	+	+	+	+
K70-80	+	+	-	+	+	+	+	+	+
K70-81	-	ND	-	+	+	+	+	+	+

[a] +, presence of the corresponding gene or genetic structure as listed in Table S3; -, interruption or absence of the corresponding gene or genetic structure as listed in Table S3; ND, not determined.